Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T P Miller

Showing results (91-100 of 130) with videos related to

Pageof 13
Sort By:
The American Journal of Pathology|October 1, 1988
The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphomaC M Spier, T M Grogan, S M Lippman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group studyJ K Weick, S Dahlberg, R I Fisher, et al.
Blood|July 1, 1991
Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizerS E Salmon, W S Dalton, T M Grogan, et al.
Anti-Cancer Drugs|December 29, 2000
Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trialC W Taylor, M LeBlanc, R I Fisher, et al.
Seminars in Hematology|April 1, 1988
Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomasT P Miller, B W Dana, J K Weick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1990
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group studyT P Miller, S Dahlberg, J K Weick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group studyT P Miller, S Dahlberg, S E Salmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1986
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experienceD O Dixon, B Neilan, S E Jones, et al.
Investigational New Drugs|January 1, 1986
Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanomaT A Braich, S E Salmon, A Robertone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphomaA T Stopeck, A Gessner, T P Miller, et al.
Pageof 13

Showing results (91-100 of 130) with videos related to

Sort By:
Pageof 13
The American Journal of Pathology|October 1, 1988
The aberrancy of immunophenotype and immunoglobulin status as indicators of prognosis in B cell diffuse large cell lymphomaC M Spier, T M Grogan, S M Lippman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1991
Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group studyJ K Weick, S Dahlberg, R I Fisher, et al.
Blood|July 1, 1991
Multidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizerS E Salmon, W S Dalton, T M Grogan, et al.
Anti-Cancer Drugs|December 29, 2000
Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trialC W Taylor, M LeBlanc, R I Fisher, et al.
Seminars in Hematology|April 1, 1988
Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomasT P Miller, B W Dana, J K Weick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1990
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group studyT P Miller, S Dahlberg, J K Weick, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1991
Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group studyT P Miller, S Dahlberg, S E Salmon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1986
Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experienceD O Dixon, B Neilan, S E Jones, et al.
Investigational New Drugs|January 1, 1986
Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanomaT A Braich, S E Salmon, A Robertone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2000
Loss of B7.2 (CD86) and intracellular adhesion molecule 1 (CD54) expression is associated with decreased tumor-infiltrating T lymphocytes in diffuse B-cell large-cell lymphomaA T Stopeck, A Gessner, T P Miller, et al.
Pageof 13